中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
5期
41-42
,共2页
卡培他滨%晚期乳腺癌%疗效%安全性
卡培他濱%晚期乳腺癌%療效%安全性
잡배타빈%만기유선암%료효%안전성
Capecitabine shore%Advanced breast cancer%Efficacy%Safety
目的:探究卡培他滨在蒽环和紫杉类失败的晚期乳腺癌中的疗效与安全性.方法:选择20例蒽环和紫杉类失败的晚期乳腺癌患者,给予卡培他滨治疗,观察临床疗效及用药安全.结果:结束化疗4周后 ORR 率为25%,5例 PR 患者均接受蒽环和紫杉类单纯使用或联合使用方案治疗.主要药物不良反应有手足综合征、食欲不振、恶心、呕吐、便秘、中性粒细胞减少,且大部分为1~2级,3~4级毒性发病率较低.结论:卡培他滨在蒽环和紫杉类失败的晚期乳腺癌患者中疗效确切,且用药较安全,口服用药方便,成为晚期乳腺癌首选药物.
目的:探究卡培他濱在蒽環和紫杉類失敗的晚期乳腺癌中的療效與安全性.方法:選擇20例蒽環和紫杉類失敗的晚期乳腺癌患者,給予卡培他濱治療,觀察臨床療效及用藥安全.結果:結束化療4週後 ORR 率為25%,5例 PR 患者均接受蒽環和紫杉類單純使用或聯閤使用方案治療.主要藥物不良反應有手足綜閤徵、食欲不振、噁心、嘔吐、便祕、中性粒細胞減少,且大部分為1~2級,3~4級毒性髮病率較低.結論:卡培他濱在蒽環和紫杉類失敗的晚期乳腺癌患者中療效確切,且用藥較安全,口服用藥方便,成為晚期乳腺癌首選藥物.
목적:탐구잡배타빈재은배화자삼류실패적만기유선암중적료효여안전성.방법:선택20례은배화자삼류실패적만기유선암환자,급여잡배타빈치료,관찰림상료효급용약안전.결과:결속화료4주후 ORR 솔위25%,5례 PR 환자균접수은배화자삼류단순사용혹연합사용방안치료.주요약물불량반응유수족종합정、식욕불진、악심、구토、편비、중성립세포감소,차대부분위1~2급,3~4급독성발병솔교저.결론:잡배타빈재은배화자삼류실패적만기유선암환자중료효학절,차용약교안전,구복용약방편,성위만기유선암수선약물.
Objective:To explore efficacy and safety of capecitabine in advanced breast cancer with anthracycline and taxane failure.Method:20 patients with anthracycline and taxane failure in patients with advanced breast cancer,capecitabine,to observe the clinical efficacy and drug safety. Result:4 weeks after the end of chemotherapy,the ORR was 25%,five cases of PR patients underwent anthracycline and taxane simple to use or joint use regimen.The main adverse drug reactions hand-foot syndrome,loss of appetite,nausea,vomiting,constipation,neutropenia,and most of 1 to 2,3 to 4 toxicity incidence is relatively low.Conclusion:The exact efficacy of capecitabine in anthracycline and taxane failure in patients with advanced breast cancer,and the drug is safer,convenient oral medication,the drug of choice for advanced breast cancer.